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Immunologic disorders related to anticonvulsant therapy have been described in the last three decades, including cellular and
humoral alterations that result in recurrent infections; however, the physiopathologic mechanisms are not completely understood.
This report describes a patient with complex partial epilepsy and hypogammaglobulinemia while in treatment with
carbamazepine, with significant improvement in clinical signs and laboratory tests after substitution to sodium valproate.
The authors stress the importance of clinical and laboratory evaluation of patients in continuous anticonvulsant therapy, including
immunoglobulins levels and peripheral blood evaluations.
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The efficacy of carbamazepine
(CBZ) for patients with epilepsy was
first demonstrated in the early 1960s.
In 1974, CBZ was first used in the
United States as an anti-epileptic drug
for adult patients with epilepsy and was
approved for children 6 years of age
and older. In 1987, CBZ was approved
for the entire pediatric age range.
CBZ is currently used for the treat-
ment of simple or complex epileptic sei-
zures and for generalized tonic-clonic
seizures. It is considered a major broad-
prescription anticonvulsant because it
produces fewer behavioral or psycho-
logical disorders than phenytoin or phe-
nobarbital1. Among the side effects of
the drug most often reported are sleep
disorders, anorexia, nausea, vomiting,
polydipsia, irritability, ataxia, and diplo-
pia. Involvement of the immune system
is demonstrated by reports of dermati-
tis, eosinophilia, lymphadenopathy, and
splenomegaly. Approximately 10% of
patients develop transitory leukopenia,
which usually resolves after an average
of 4 months of continued treatment,
while 2% of these patients develop per-
sistent leukopenia requiring discontinu-
ation of the drug2.
Involvement of the immune system
has been studied since the drug was
first used, and according to Sorrel and
Forbes3, affects as many as 47% of the
patients treated with CBZ. Among the
changes described are IgA and IgM de-
ficiency, and reduced DNA and RNA
synthesis in circulating leukocytes and
in cultured lymphocytes stimulated
with phytohemagglutinin (PHA)3. De-
creased serum IgG levels have been re-
ported in a few studies and in isolated
clinical cases4-7, with the reduction in
IgA being the change most commonly
noted3,8-11 .
The physiopathological mecha-
nisms of the side effects of the drug on
the immune system have not been fully
elucidated, but they do not seem to de-
pend on the dose or on the serum con-
centration of the drug, or on the dura-
tion of treatment3.
We report here a patient with com-
plex partial epilepsy who presented
hypogammaglobulinemia after begin-
ning treatment with CBZ and who
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showed clinical and laboratory im-
provement after the drug was replaced
with valproic acid.
CASE REPORT
A 7-year-old boy followed on an
ambulatory basis because of moderate
asthma and allergic rhinitis, which had
started at 1 year and 6 months of age
and had been clinically controlled after
3 years, had been free of repeated infec-
tions up to the age of 6 years. Labora-
tory tests carried out at the beginning of
ambulatory follow-up showed normal
IgA and IgM levels, elevated IgE lev-
els, and a blood count with moderate
eosinophilia (9%), compatible with the
atopic picture. The parents denied a
family history of immunodeficiency,
epilepsy, or consanguinity.
At 6 years of age the patient started
to have recurrent complex partial epi-
leptic seizures, with a personal history
of fever-induced convulsions at 18
months of age and absence of impair-
ment of neuropsychomotor develop-
ment. On evaluation by a neuro-
pediatrician, he presented focal irrita-
tive occipitotemporal activity on the
right in the encephalogram and normal
skull computed tomography and nu-
clear magnetic resonance of the nerv-
ous system. Epilepsy was diagnosed,
and treatment with carbamazepine was
started (400 mg/day). After 1 month of
continued CBZ use, the patient started
to have recurrent infections — about 9
episodes of sinusitis in 18 months —
requiring prolonged antibiotic treat-
ment. The blood counts performed dur-
ing this period did not show significant
leukocyte changes but did reveal an in-
crease to 25% in eosinophilia (1500/
mm3). The occurrence of repeated in-
fections motivated a new immuno-
globulin determination 8 months after
the introduction of CBZ, which
showed a significant reduction in IgA
levels from 100 to 16 mg/dL and in
IgG levels from 1038 to 594 mg/dL,
and maintenance of IgM levels (Fig. 1).
Serum levels of the IgG subclasses
showed a preponderant fall in IgG2 to
82 mg/dL (normal range: 119 to 480
mg/dL ). The evaluation of IgM anti-
bodies by isohemagglutinin determina-
tion was found to be normal, and
evaluation of functional IgG by mea-
sles serology was negative. Cellular
immunity investigated by white cell
count, CD4/CD8 count, and lym-
phocyte proliferation after stimulation
with PHA was normal.
Figure 2 - IgA seric levels before, during and after carbamazepine.
# - Normal ranges of Brazilian children - Naspitz et al., J Ped, 52(3): 1982.
Figure 1 - IgG seric levels before, during and after carbamazepine.
# - Normal ranges of Brazilian children - Naspitz et al., J Ped, 52(3): 1982.
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CBZ was replaced with valproic
acid, and 8 months after the discon-
tinuation of CBZ, there was a reduction
in the episodes of sinusitis, and no
other airway infections were observed.
An increase in serum IgA and IgG lev-
els occurred in parallel, with no need
for other therapeutic measures.
DISCUSSION
The immunologic changes ob-
served in patients treated with anti-
convulsants deserve consideration be-
cause of their frequency and possible
clinical repercussions.
Although phenytoin is the drug
most extensively studied because of its
frequent effects on the immune system,
other anticonvulsants can also have
similar effects, as observed in the spe-
cific case in question in which hypo-
gammaglobulinemia developed after
the use of CBZ.
After the approval of the use of
CBZ for the treatment of convulsive
seizures in 1974, several studies have
evaluated the repercussions of this
medication on the immune system3-16.
The alterations in cellular immunity
have been extensively studied3, but the
serum concentration and function of
immunoglobulins still receives special
attention in the literature. Few studies
have evaluated the exclusive participa-
tion of CBZ in the genesis of changes
in the immune system, since convul-
sive patients are often undergoing
multidrug therapy, including pheny-
toin, a fact that prevents conclusions
about this matter. In addition, when the
relationship of CBZ to immunoglobu-
lin levels is evaluated, data from the lit-
erature are often contradictory. The re-
duction in serum IgA levels is the
change most frequently reported after
the use of anticonvulsants, with total
and partial immunodeficiency having
been reported3,8,9-11. Symptoms similar
to those of patients with primary IgA
deficiency may arise in these patients,
such as recurrent infections, greater
prevalence of atopy, autoimmune dis-
eases such as systemic lupus erythema-
tosus, and lymphoproliferative diseases
such as lymphomas11. Gilhus et al.9,11-
14 concluded that the immunologic al-
terations presented by epileptic patients
may be related to the use of anti-
convulsants rather than being second-
ary to the base disease. However, some
authors suggest an association between
epilepsy and changes in the immune
system, a fact that impairs the estab-
lishment of a causative relation16. The
patient reported here did not present
signs or symptoms suggestive of im-
munodeficiency before the introduc-
tion of CBZ, and his serum IgM, IgG,
and IgA levels were normal. The sub-
sequent reduction of these last two
immunoglobulins, which are funda-
mental for protection against infec-
tions, suggests the occurrence of im-
munodeficiency secondary to the anti-
convulsant.
The reduction in immunoglobulin
levels induced by the use of anti-
convulsants may be genetically deter-
mined. There are studies showing an
important relation between some types
of HLA and the immunoglobulin defi-
ciency induced by this agent. HLA-A2
is related to the IgA deficiency induced
by phenytoin, and HLA-A1B may be
related to the reduction in immu-
noglobulin levels produced by CBZ12,15.
The reduction in serum IgG by the
use of anticonvulsants is a controver-
sial matter in the literature. Most of the
studies on the immunologic behavior
of CBZ users reported no variations in
IgG levels, but rather a decrease in se-
rum IgA and IgM levels3,8-11, with few
reports of changes in IgG concentra-
tions related to CBZ use4-7.
The mechanism by which anticon-
vulsants interfere with the immune sys-
tem is not understood. Spickett et al.5
suggested the occurrence of interac-
tions between cells of the central nerv-
ous system and the immune system as-
sociated with the use of anticon-
vulsants, with no elucidation of the
physiopathological process involved.
Even the causes of leukopenia, the
most frequent immunologic alteration,
are not fully defined. However, Gilhus
and Matre13 evaluated 10 patients un-
dergoing treatment with CBZ and ob-
served that those presenting reduced
serum IgA and IgM had no reduction
in the number of T or B lymphocytes
or in their proliferating ability, suggest-
ing a defect in B lymphocyte matura-
tion or in immunoglobulin synthesis. In
cases progressing to leukopenia or a
fall in T lymphocytes with hypo-
gammaglobulinemia, this humoral de-
ficiency may be due to the reduction
of B lymphocyte activation by T
lymphocytes.
In the studies reviewed, no corre-
lation was observed between the im-
munologic changes and the serum con-
centration of the drug or the combined
use of other anticonvulsants2-6.
Andersen et al.4 reported a more
marked reduction in IgG and IgA in
females compared to males.
The recovery of serum immu-
noglobulin levels usually occurs 4
months to 6 years after the discontinu-
ation of anticonvulsant medication11. In
the present case, a progressive increase
in serum IgA and IgG levels towards
normal limits occurred 8 months after
withdrawal of CBZ, coinciding with a
decreased occurrence of infections.
According to Schiff, IgG values higher
than 500 mg/dL are considered to be
protective in patients with a gamma-
globulinemia who receive intravenous
gammaglobulin replacement, a fact that
considerably reduces the recurrence of
infections.
CBZ continues to be the drug of
first choice for the treatment of partial
epilepsy, but some precautions should
be taken. The present reports calls at-
tention to the need for clinical and
laboratory follow-up of CBZ users
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since changes in the immune system
lead to an increased prevalence of in-
fections, autoimmune, and even neo-
plastic diseases. The professionals who
habitually prescribe anticonvulsants –
and CBZ in particular – should be alert
to these changes, and when they occur,
specific immunologic evaluation
should be requested17.
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As alterações imunológicas relaci-
onadas ao uso de anti-convulsivantes
têm sido descrita há três décadas, en-
volvendo alterações celulares e humo-
rais, sendo os mecanismos fisiopatoló-
gicos ainda não totalmente elucidados.
Este relato descreve o caso de paci-
ente portador de epilepsia parcial com-
plexa com hipogamaglobulinemia du-
rante o tratamento com carbamazepina,
tendo apresentado melhora clínica e
laboratorial importantes após substitui-
ção da droga pelo ácido valpróico.
Os autores ressaltam a importância
do acompanhamento clínico e labora-
torial, incluindo avaliação dos níveis de
imunoglobulinas e hemogramas seria-
dos dos pacientes em uso contínuo de
anticonvulsivantes.
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